China's Pharmaceutical Intermediates Producers Plan US$1.88 Billion in Project Kickoffs for 2022

---

Researched by Industrial Info Resources (Sugar Land, Texas)--China's carbon neutrality and emissions policy has had an impact on a few of the country's chemical synthetic pharmaceutical plants, but that hasn't stopped plans for new projects.

Industrial Info is tracking 78 active capital pharmaceutical intermediates projects in China, with a combined investment value of more than US$300 billion. This includes 26 projects under construction, worth $1.02 billion, and 46 projects, worth $1.88 billion, that are planned to kick off construction in 2022. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a list of detailed project reports.

Anhui Jinquan Biotechnology Company Limited has more than US$164.9 million in planned projects. It is followed by Henan Weiyuan Biotechnology Company Limited and Huangshi Fertai Pharmaceutical Tech Company Limited.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.